Xiangju Capsules Efficacy and Safety for Allergic Rhinitis: Meta-Analysis of 14 RCTs

Min Chen published a systematic review and meta-analysis on May 28, 2026, evaluating the efficacy and safety of Xiangju capsules for allergic rhinitis. The analysis synthesizes data from 14 randomized controlled trials involving 1,968 patients, reporting on clinical symptom scores and immunological markers. The review is registered with PROSPERO (CRD420261279480) and the document is shared under a CC-BY-4.0 license.

Use Cases

• Assess the overall effectiveness of Xiangju capsules based on reported effective rates from the meta-analysis.
• Analyze changes in specific allergic rhinitis symptoms based on reported runny nose and sneezing scores.
• Evaluate immunological response based on reported levels of IL-4, IgE, and IL-12 biomarkers.
• Compare safety profiles based on reported adverse event incidence between treatment groups.

Strengths

• Analysis is based on 14 randomized controlled trials involving 1,968 patients.
• Methodology includes subgroup analyses, sensitivity analyses, and publication bias assessment using funnel plots and statistical tests.
• Evidence quality was graded using the Cochrane Risk of Bias tool and the GRADE framework.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• The authors note the limited certainty of the evidence, suggesting further high-quality studies are needed.

Provenance

Source

Min Chen

Collection Method

Systematic review and meta-analysis of data from eight Chinese and English databases.

Time Range

Data searched from inception to November 30, 2025.

Freshness

Last updated 2026-05-28 08:27:08; freshness should be verified.